Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2000-4-11
pubmed:abstractText
Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or metastatic pancreatic cancer with improvement of both quality of life and survival time. The response of the tumour marker CA 19-9 to chemotherapy with gemcitabine was studied in order to find out whether it is related to survival time of patients. Forty-three consecutive patients (median age 61 years, range 39-76 years; 20 males, 23 females) suffering from histologically proven locally advanced or metastatic pancreatic adenocarcinoma and a baseline Karnofsky-index > or = 60 were treated with gemcitabine in a dose of 1,000 mg/m(-2) weekly x 7 followed by 1 week of rest during the first cycle and thereafter 1,000 mg/m(-2) weekly x 3 followed by 1 week of rest until progression. In 36 of 43 patients serial measurements of CA 19-9 could be performed. Patients with a decrease of > 20% of the baseline CA 19-9 level after 8 weeks of treatment (n = 25) had a significantly better median survival than patients with a rise or a decrease < or = 20% (n = 11) (268 vs 110 days; P < 0.001). The response of CA 19-9 was the strongest independent predictor of survival (P < 0.001) in the multivariate analysis. In conclusion, a decrease of CA 19-9 > 20% during the first weeks of chemotherapy with gemcitabine is associated with a better survival of patients with locally advanced or metastatic pancreatic cancer. Serial measurements of CA 19-9 are useful to decide whether further chemotherapy after the first weeks of treatment is indicated.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-1348409, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-2930108, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-3162513, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-7510116, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-8554969, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-8623058, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-8681301, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-8681304, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-8805925, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-8830333, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-9196156, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-9461005, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-94699, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-9496523, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-9607356, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-9625429, http://linkedlifedata.com/resource/pubmed/commentcorrection/10737382-9684148
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1013-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
pubmed:affiliation
Department of Internal Medicine II, University of Leipzig, Germany.
pubmed:publicationType
Journal Article